JP2012502105A5 - - Google Patents

Download PDF

Info

Publication number
JP2012502105A5
JP2012502105A5 JP2011526972A JP2011526972A JP2012502105A5 JP 2012502105 A5 JP2012502105 A5 JP 2012502105A5 JP 2011526972 A JP2011526972 A JP 2011526972A JP 2011526972 A JP2011526972 A JP 2011526972A JP 2012502105 A5 JP2012502105 A5 JP 2012502105A5
Authority
JP
Japan
Prior art keywords
iloperidone
patient
cyp2d6
disorder
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011526972A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012502105A (ja
Filing date
Publication date
Priority claimed from US12/208,027 external-priority patent/US20100063093A1/en
Application filed filed Critical
Publication of JP2012502105A publication Critical patent/JP2012502105A/ja
Publication of JP2012502105A5 publication Critical patent/JP2012502105A5/ja
Pending legal-status Critical Current

Links

JP2011526972A 2008-09-10 2009-09-10 イロペリドンの投与方法 Pending JP2012502105A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/208,027 2008-09-10
US12/208,027 US20100063093A1 (en) 2007-03-28 2008-09-10 Methods for the administration of iloperidone
PCT/US2009/056517 WO2010030783A1 (en) 2008-09-10 2009-09-10 Methods for the administration of iloperidone

Publications (2)

Publication Number Publication Date
JP2012502105A JP2012502105A (ja) 2012-01-26
JP2012502105A5 true JP2012502105A5 (cg-RX-API-DMAC10.html) 2012-11-01

Family

ID=41280442

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011526972A Pending JP2012502105A (ja) 2008-09-10 2009-09-10 イロペリドンの投与方法

Country Status (8)

Country Link
US (5) US20100063093A1 (cg-RX-API-DMAC10.html)
EP (2) EP2331098B1 (cg-RX-API-DMAC10.html)
JP (1) JP2012502105A (cg-RX-API-DMAC10.html)
AU (1) AU2009291717A1 (cg-RX-API-DMAC10.html)
CA (1) CA2736245C (cg-RX-API-DMAC10.html)
ES (1) ES2688476T3 (cg-RX-API-DMAC10.html)
SI (1) SI2331098T1 (cg-RX-API-DMAC10.html)
WO (1) WO2010030783A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100063093A1 (en) * 2007-03-28 2010-03-11 Curt Wolfgang Methods for the administration of iloperidone
CA3113166A1 (en) 2004-09-30 2006-04-13 Vanda Pharmaceuticals Inc. Methods for the administration of iloperidone
KR20170008327A (ko) * 2012-03-14 2017-01-23 반다 파마슈티칼즈, 인코퍼레이티드. 정신적 질환의 치료 용도를 위한 일로페리돈 대사물질
CN116211857A (zh) 2015-02-17 2023-06-06 万达制药公司 用于治疗精神分裂症的伊潘立酮
US11214827B2 (en) * 2018-08-30 2022-01-04 Vanda Pharmaceuticals Inc. Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965188A (en) * 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US5130238A (en) * 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US5364866A (en) * 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
GB9001181D0 (en) * 1990-01-18 1990-03-21 Imp Cancer Res Tech Genetic assay
US5846717A (en) * 1996-01-24 1998-12-08 Third Wave Technologies, Inc. Detection of nucleic acid sequences by invader-directed cleavage
WO2000055624A2 (en) 1999-03-15 2000-09-21 Leyland Jones Brian Elisa kit for the determination of metabolic phenotypes
IL145451A0 (en) * 1999-04-07 2002-06-30 Pfizer Prod Inc Use of cyp2d6 inhibitors in combination therapies
US20010034023A1 (en) * 1999-04-26 2001-10-25 Stanton Vincent P. Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing
US6960439B2 (en) * 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US7250252B2 (en) 1999-12-30 2007-07-31 David Aaron Katz Amplification based polymorphism detection
EP1290220B1 (en) * 2000-04-13 2007-12-19 Georgetown University Genetic diagnosis of qt prolongations as adverse drug reactions
US6761895B2 (en) * 2000-04-17 2004-07-13 Yamanouchi Pharmaceutical Co., Ltd. Drug delivery system for averting pharmacokinetic drug interaction and method thereof
AU2001275475A1 (en) * 2000-06-12 2001-12-24 Genicon Sciences Corporation Assay for genetic polymorphisms using scattered light detectable labels
US20020022254A1 (en) 2000-07-28 2002-02-21 Karl Guegler Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
WO2002044994A2 (en) 2000-11-30 2002-06-06 Third Wave Technologies, Inc. Systems and methods for detection assay ordering, design, production, inventory, sales and analysis for use with or in a production facility
GB0102841D0 (en) 2001-02-05 2001-03-21 Novartis Ag Organic compounds
WO2002073196A2 (en) * 2001-03-14 2002-09-19 Mcgill University Individualization of therapy with antipsychotics
EP1339879A4 (en) 2001-06-05 2004-12-29 Genaissance Pharmaceuticals METHOD OF IDENTIFYING POLYMORPHISM IN CYP2D6
WO2004009760A2 (en) 2002-07-18 2004-01-29 Bioventures, Inc. Cytochrome p450 genetic variations
US7195877B2 (en) * 2001-07-20 2007-03-27 Bioventures, Inc. Cytochrome P450 genetic variations
EP1281755A3 (en) * 2001-07-31 2003-06-18 Pfizer Products Inc. Variants of the human cyp2d6 gene
JP2005525292A (ja) 2001-08-24 2005-08-25 アリックス セラピューティクス 非酸化的に代謝される化合物および組成物、それらの合成経路、ならびに使用方法
ES2370634T3 (es) * 2001-08-31 2011-12-21 Novartis Ag Isómeros ópticos de un metabolito de iloperidona.
CA2463158C (en) * 2001-10-30 2013-07-30 Novartis Ag Depot formulations of iloperidone and a star polymer
JP2005507261A (ja) 2001-10-31 2005-03-17 ノバルティス アクチエンゲゼルシャフト Ｔｃｆ１遺伝子における多型に基づく糖尿病および関連状態の治療方法
ATE503845T1 (de) 2001-12-10 2011-04-15 Novartis Pharma Gmbh Verfahren zur behandlung von psychosen und schizophrenie auf der basis eines polymorphismus im cntf gen
US20040096874A1 (en) * 2002-04-11 2004-05-20 Third Wave Technologies, Inc. Characterization of CYP 2D6 genotypes
US20040091909A1 (en) * 2002-07-05 2004-05-13 Huang Doug Hui High throughput cytochrome P450 genotyping
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US8401801B2 (en) 2003-02-20 2013-03-19 Mayo Foundation For Medical Education And Research Methods for selecting medications
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US20050032070A1 (en) * 2003-08-05 2005-02-10 Sebastian Raimundo Polymorphisms in the human gene for CYP2D6 and their use in diagnostic and therapeutic applications
US20080166357A1 (en) * 2004-05-11 2008-07-10 Stefan Golz Diagnostics and Therapeutics for Diseases Associated with Dipeptidyl-Peptidase 6 (Dpp6)
CA3113166A1 (en) * 2004-09-30 2006-04-13 Vanda Pharmaceuticals Inc. Methods for the administration of iloperidone
US20100063093A1 (en) * 2007-03-28 2010-03-11 Curt Wolfgang Methods for the administration of iloperidone
US20150259747A1 (en) 2007-03-29 2015-09-17 Vanda Pharmaceuticals Inc. Method of predicting a predisposition to qt prolongation
JP5586094B2 (ja) * 2007-03-29 2014-09-10 ヴァンダ ファーマシューティカルズ インコーポレイテッド Ｑｔ延長に対する素因を予測する方法
EP3075865B1 (en) 2007-05-18 2018-05-09 Vanda Pharmaceuticals Inc. Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms
WO2009036056A1 (en) 2007-09-10 2009-03-19 Vanda Pharmaceuticals, Inc. Antipsychotic treatment based on snp genotype
JP5653753B2 (ja) 2007-09-10 2015-01-14 ヴァンダ ファーマシューティカルズ インコーポレイテッド Ｓｎｐ遺伝子型に基づくｑｔ延長の予測
CA2757723C (en) 2009-04-06 2018-07-24 Vanda Pharmaceuticals, Inc. Method of predicting a predisposition to qt prolongation based on abcc2 gene sequence or product thereof
EP3354753B1 (en) 2009-04-06 2020-02-12 Vanda Pharmaceuticals Inc. Method of treatment based on polymorphisms of the kcnq1 gene
JP5881597B2 (ja) 2009-04-06 2016-03-09 ヴァンダ ファーマシューティカルズ インコーポレイテッド Ｑｔ延長に対する素因を予測する方法
EP2416779B1 (en) 2009-04-06 2016-03-09 Vanda Pharmaceuticals Inc. Method of predicting a predisposition to qt prolongation based on bai3 gene sequence or product thereof
WO2010132866A1 (en) 2009-05-15 2010-11-18 Vanda Pharmaceuticals Inc. Antipsychotic treatment based on drd2 or ankk1 snp genotype
KR20170008327A (ko) 2012-03-14 2017-01-23 반다 파마슈티칼즈, 인코퍼레이티드. 정신적 질환의 치료 용도를 위한 일로페리돈 대사물질
US11071728B2 (en) 2015-12-11 2021-07-27 Vanda Pharmaceuticals Inc. Treatment of schizophrenia
US11214827B2 (en) 2018-08-30 2022-01-04 Vanda Pharmaceuticals Inc. Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone
US11607408B2 (en) 2019-10-15 2023-03-21 Vanda Pharmaceuticals Inc. Method of treatment of schizophrenia

Similar Documents

Publication Publication Date Title
van Noord et al. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease
JP2014517050A5 (cg-RX-API-DMAC10.html)
JP2014528474A5 (cg-RX-API-DMAC10.html)
JP2014515373A5 (cg-RX-API-DMAC10.html)
JP2002532392A5 (cg-RX-API-DMAC10.html)
JP2021080276A (ja) デクスメデトミジン製剤を使用する睡眠障害の予防または治療
JP2010526837A5 (cg-RX-API-DMAC10.html)
JP2013541583A5 (cg-RX-API-DMAC10.html)
JP2024016113A (ja) ハンチントン病及びその症状を治療するためのプリドピジン及びその類似体を含む組成物
HRP20150438T1 (hr) Uporaba lizosomalne kiselinske lipaze za lijeäśenje deficijencije lizosomalne kiselinske lipaze kod pacijenata
JP2014514271A5 (cg-RX-API-DMAC10.html)
WO2006017816A3 (en) Product and process for inhibition of biofilm development
JP2013516493A5 (cg-RX-API-DMAC10.html)
JP2013518124A5 (cg-RX-API-DMAC10.html)
JP2017528521A5 (cg-RX-API-DMAC10.html)
JP2012502103A5 (cg-RX-API-DMAC10.html)
JP2024501919A5 (cg-RX-API-DMAC10.html)
JP2013536837A5 (cg-RX-API-DMAC10.html)
JP2016505050A5 (cg-RX-API-DMAC10.html)
ES2773711T3 (es) Un metabolito de iloperidona para uso en el tratamiento de trastornos psiquiátricos
JP2011500589A5 (cg-RX-API-DMAC10.html)
JP2013536206A5 (cg-RX-API-DMAC10.html)
Avital et al. Zolmitriptan compared to propranolol in the treatment of acute neuroleptic-induced akathisia: a comparative double-blind study
TWI841027B (zh) 手部溼疹之治療
RU2013112890A (ru) Терапевтическое применение 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина